Re Cytotoxic surveillance
It seems that I cannot get a definitive answer regarding surveillance.
We perform a baseline FBC for cytotoxic handlers prior to their exposure
to see if there is a pre-existing condition. We only perform a repeat
test one month after a significant occupational exposure such as
needlestick injury, skin contamination or unreconstituted or
reconstituted drugs, inhalation of powder for accidental vial
breakages.
We also send an annual questionnaire to cytotoxic handlers to ascertain
any unreported significant exposure, unusual illness, pregnancy or birth
defects.
Having looked at lots of research for one of my degree assignments I
found a tremendous range of surveillance from nil to regular blood tests
or urine mutagenicity screening.
The HSE have published recent research about cytotoxic drugs including
their preparation and handling in an isolator but I cannot locate the
reference for you. However, have a look at the American Occupational
Health & Safety Administration handbook as there is a whole chapter
relating to hazardous drugs including cytotoxic/ antineoplastic drugs.
http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html#6
It would be helpful to be updated.
Paul D'Arcy,
Occupational Health Manager (Acting)
Occupational Health
Hammersmith Hospital
Developing And Supporting People To Make Healthcare Better
Direct Line 020 8383 1024
Internal Ext 31024
*
**
Confidentiality Notice
The contents of this e-mail are confidential to the ordinary user of the e-mail address to which it is addressed and may also be privileged. If you are not the addressee of this e-mail you may not copy, forward, disclose or otherwise use it in any form whatsoever. If you have received this e-mail in error please telephone the Hammersmith Hospitals NHS Trust IT department on 020 8746 5555. Please also delete the message from your computer.
**
*
|